Clinical trials: First Line Treatment
Small-bowel Adenocarcinoma, Metastatic Disease
First-line Treatment in Locally Advanced or Metastastic Small Bowel Adenocarcinoma
Phase II randomized trial evaluating modified FOLFIRINOX and FOLFOX in the treatment of locally advanced or metastatic small bowel adenocarcinoma
- Conditions
- Small-bowel Adenocarcinoma, Metastatic Disease, Chemotherapy Effect
- Trial name
- FIRE-12 (NCT07844057)
- Testing
- mFOLFIRINOX versus FOLFOX chemotherapy
- Where
- 16 sites in Germany
- Volunteers
- 86 people
- Sponsor
- Annika Kurreck
Small Cell Lung Cancer
Adebrelimab Plus Apatinib for Maintenance Therapy of Extensive Stage Small Cell Lung Cancer
To evaluate the efficacy and safety of maintenance therapy with Adebrelimab plus Apatinib for extensive stage small cell lung cancer after first-line induction of Adebrelimab plus chemotherapy.
- Trial name
- NCT06480864
- Testing
- Adebrelimab Injection, Apatinib Mesylate Tablets, Carboplatin
- Where
- 2 sites in China
- Volunteers
- 38 people
- Sponsor
- Yunpeng Liu
Metastatic Lung Cancer, Stage IV Lung Cancer
Immunotherapy With or Without SBRT in Patients With Stage IV Non-small Cell Lung Cancer
This phase III trial studies immunotherapy and stereotactic body radiation therapy to see how well it works compared with immunotherapy alone after first-line systemic therapy (therapy that goes throughout the body) in treating…
- Trial name
- NCT03867175
- Testing
- Stereotactic Body Radiation Therapy, Pembrolizumab
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Wake Forest University Health Sciences
Renal Cell Carcinoma
Efficacy and Safety Comparison of RAD001 Versus Sunitinib in the First-line and Second-line Treatment of Patients With Metastatic Renal Cell Carcinoma
This study assessed the efficacy and safety of first-line RAD001 followed by second-line sunitinib versus the opposite sequence: first-line sunitinib followed by second-line RAD001 for the treatment of patients with MRCC.
- Trial name
- RECORD-3 (NCT00903175)
- Testing
- everolimus, sunitinib
- Where
- 84 sites in United States, Argentina and 17 more
- Volunteers
- 471 people
- Sponsor
- Novartis Pharmaceuticals
Helicobacter Pylori Infection
Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication
Bismuth-containing quadruple therapy was recommended as a first-line treatment for Helicobacter pylori infection. This study aimed to compare real-world outcomes of various bismuth-containging quadruple regimens and identify…
- Trial name
- RETRO-HP (NCT07167511)
- Testing
- This study is a retrospective study, and all data have been collected in advance with no active intervention required.
- Where
- China
- Volunteers
- 1,730 people
- Sponsor
- Yueyue Li
Aspergillosis, Invasive Fungal Infection
Isavuconazole (BAL8557) for Primary Treatment of Invasive Aspergillosis
The purpose of this study is to compare the efficacy and safety of isavuconazole versus voriconazole in the treatment of patients with invasive aspergillosis.
- Trial name
- NCT00412893
- Testing
- Isavuconazole, Voriconazole
- Where
- 107 sites in United States, Argentina and 24 more
- Volunteers
- 527 people
- Sponsor
- Astellas Pharma Inc
Ovarian Cancer
A Study of Fluzoparib Combined With QL1101 Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
This is a Prospective,Single-Center, Single-Arm, Phase 2 study to evaluate the efficacy and safety of Fluzoparib Combined With QL1101, as maintenance treatment, in patients with Advanced FIGO Stage III or IV High Grade Serous or…
- Trial name
- NCT05585281
- Testing
- Fluzoparib, QL1101
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Yongpeng Wang
Lung Cancer, Small Cell
Efficacy and Safety of First-line Treatment for Extensive-stage Small Cell Lung Cancer Using a Combination Therapy of Trilaciclib, Envafolimab, Etoposide, and Carboplatin
This prospective, randomized, controlled phase II study aims to evaluate the efficacy of combination therapy with Envafolimab and chemotherapy in first-line extensive stage SCLC, as well as the impact of Trilaciclib on the…
- Trial name
- NCT06698965
- Testing
- Chemotherapy （Etoposide and Carboplatin）, Immunotherapy （Envafolimab）, Trilaciclib
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Shanghai Chest Hospital
Gastric Cancer
Docetaxel and Epirubicin as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Adenocarcinoma of the Stomach
RATIONALE: Drugs used in chemotherapy, such as docetaxel and epirubicin, work in different ways to stop tumor cells from dividing so they stop growing or die. Giving more than one drug may kill more tumor cells.
- Trial name
- NCT00075465
- Testing
- docetaxel, epirubicin hydrochloride
- Where
- 23 sites in France
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Gastric Cancer
POF Versus FOLFOX Plus IP Paclitaxel in AGC
The aim of this study was to compare the efficacy and safety of intravenous or intraperitoneal paclitaxel plus FOLFOX as first-line treatment in AGC with peritoneal metastases, a phase II Clinical trial.
- Trial name
- NCT04155671
- Testing
- POF, FOLFOX plus PAC(ip)
- Volunteers
- 260 people
- Sponsor
- Fujian Cancer Hospital
Pancreatic Cancer, Metastatic Pancreatic Cancer
A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer
Zolbetuximab is being studied as a treatment for people with pancreatic cancer. Most people with pancreatic cancer have a protein called Claudin 18.2 (CLDN18.2) in their tumor.
- Conditions
- Pancreatic Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma
- Trial name
- NCT03816163
- Testing
- zolbetuximab, nab-paclitaxel, gemcitabine
- Where
- 136 sites in United States, Australia and 11 more
- Volunteers
- 393 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Carcinoma, Hepatocellular
Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)
The purpose of this study is to evaluate the safety and efficacy of lenvatinib (E7080/MK-7902) in combination with pembrolizumab (MK-3745) versus lenvatinib in combination with placebo as first-line therapy for the treatment of…
- Trial name
- NCT03713593
- Testing
- lenvatinib, pembrolizumab
- Where
- 172 sites in United States, Australia and 19 more
- Volunteers
- 794 people
- Sponsor
- Merck Sharp & Dohme LLC
Temporomandibular Disorders (TMDs), Temporomandibular Joint Disc Displacement, Without Reduction
Clinical Outcomes of First-Line Temporomandibular Joint Arthrocentesis Versus Arthrocentesis Following Anti-Inflammatory Treatment
This prospective comparative clinical study evaluates the clinical outcomes of temporomandibular joint arthrocentesis in patients diagnosed with disc displacement without reduction.
- Trial name
- NCT07914465
- Testing
- Temporomandibular Joint Arthrocentesis
- Where
- Turkey (Türkiye)
- Volunteers
- 28 people
- Sponsor
- Bahçeşehir University
Prostatic Neoplasms
Addition of Enzalutamide to First Line Docetaxel for Castration Resistant Prostate Cancer
The aim of this study is to verify if the addition of enzalutamide to docetaxel is able to improve the disease control in first line CRPC patients.
- Trial name
- CHEIRON (NCT02453009)
- Testing
- Docetaxel, Prednisone, Enzalutamide
- Where
- Italy
- Volunteers
- 246 people
- Sponsor
- Santa Chiara Hospital
Advanced Hepatocellular Carcinoma, Inoperable Hepatocellular Carcinoma
A Study of the Effectiveness and Safety of AMG 386 and Sorafenib to Treat Advanced or Inoperable Hepatocellular Cancer
The purpose of this study is to determine whether AMG 386, in combination with Sorafenib, is effective in the treatment of advanced or inoperable Hepatocellular cancer in subjects who have not received any prior systemic therapy…
- Trial name
- NCT00872014
- Testing
- AMG 386, Sorafenib
- Volunteers
- 60 people
- Sponsor
- Amgen
EGFR Positive Non-Small Cell Lung Cancer,Adenocarcinoma
Icotinib Combined With Dihydroaremisinin (DHA) Therapy in Patients With Advanced NSCLC
The study was to evaluate the safety, PFS and ORR of icotinib/dihydroaremisinin (DHA)-based combination therapy in EGFR-mutated, advanced NSCLC patients who have gradually progressed disease after first-line icotinib treatment.
- Trial name
- NCT03402464
- Testing
- Icotinib combined dihydroaremisinin
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Peking University Cancer Hospital & Institute
Locally Advanced or Metastatic and Unresectable HCC
A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC
This is a randomized, open-label, international, multi-center, phase III trial to evaluate the efficacy and safety of SHR-1210 plus apatinib mesylate versus sorafenib as first-line therapy in patients with advanced HCC.
- Trial name
- NCT03764293
- Testing
- SHR-1210, Apatinib, Sorafenib
- Where
- 121 sites in United States, Belgium and 11 more
- Volunteers
- 543 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Gastric Adenocarcinoma, GEJ Adenocarcinoma
Fruquintinib Combined With PD-1 Inhibitor as First-line Maintenance Therapy for Advanced Gastric Cancer
This study was designed to explore the efficacy and safety of fruquintinib combined with PD-1 inhibitors as first-line maintenance therapy for advanced HER-2 Negative Gastric Cancer.
- Conditions
- Gastric Adenocarcinoma, GEJ Adenocarcinoma, First-line Therapy, Maintenance Therapy
- Trial name
- NCT06888037
- Testing
- Initial treatment: PD-1+ Oxaliplatin-based chemotherapy (CAPOX/SOX/FOLFOX）, Maintenance treatment (after 3 months): fruquintinib+PD-1
- Where
- China
- Volunteers
- 55 people
- Sponsor
- Ruijin Hospital
Type 2 Diabetes
INSPIRE Diabetes Study: Basal Bolus Insulin as Primary Treatment of Type 2 Diabetes
T2DM has become an American Epidemic. Currently 8% of the US population has diabetes and rates may be as high as 33% by the year 2050 (1).
- Trial name
- INSPIRE (NCT01087567)
- Testing
- Intensive insulin, Routine Care
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Ohio University
Non-Small-Cell Lung Cancer
Efficacy and Safety of Combination Therapy of Sintilimab and Chemotherapy With Cryoablation in NSCLC
This study aims to investigate the efficacy and safety of immuno-chemotherapy in combination of cryoablation as the first-line treatment of advanced NSCLC
- Trial name
- NCT06483009
- Testing
- Cryoablation
- Volunteers
- 20 people
- Sponsor
- Shanghai Chest Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.